Immunotech Laboratories, Inc.
Other OTCTotal Valuation
Immunotech Laboratories, Inc. carries a market capitalization of 114,993.00, placing it among publicly traded companies globally. Its enterprise value stands at 469,209.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 114,993.00 |
| Enterprise Value | 469,209.00 |
Share Statistics
Immunotech Laboratories, Inc. currently has 263,175.00 shares outstanding.
| Shares Outstanding | 263,175.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 156.93 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Immunotech Laboratories, Inc. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.06 |
| Quick Ratio | 0.01 |
| Debt / Equity | -23.17 |
| Debt / EBITDA | -0.17 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -18,563.89 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.00 |
Stock Price Statistics
Immunotech Laboratories, Inc.'s stock has gained approximately 100.00001% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 100.00001% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Immunotech Laboratories, Inc. generated 2,990.00 in revenue and converted that into -37.11M in net income, yielding earnings per share of -154.35. EBITDA reached -2.88M, while operating income came in at -2.88M.
| Revenue | 2,990.00 |
| Gross Profit | 2,753.00 |
| Operating Income | -2.88M |
| Pretax Income | -1.69M |
| Net Income | -37.11M |
| EBITDA | -2.88M |
| EBIT | -2.88M |
| Earnings Per Share (EPS) | -154.35 |
Balance Sheet
Immunotech Laboratories, Inc. holds 18,530.00 in cash and equivalents against 483,739.00 in total debt, resulting in a net debt position of 465,209.00. Total book value stands at -76.52M, with working capital of -2.32M providing operational flexibility.
| Cash & Cash Equivalents | 18,530.00 |
| Total Debt | 483,739.00 |
| Net Debt | 465,209.00 |
| Equity (Book Value) | -76.52M |
| Book Value Per Share | -318.23 |
| Working Capital | -2.32M |
Cash Flow
Immunotech Laboratories, Inc. produced -301,205.00 in operating cash flow over the past twelve months. After subtracting -122,898.00 in capital expenditures, free cash flow totaled -424,103.00 - equivalent to -1.76 per share.
| Operating Cash Flow | -301,205.00 |
| Capital Expenditures | -122,898.00 |
| Free Cash Flow | -424,103.00 |
| FCF Per Share | -1.76 |
Margins
Immunotech Laboratories, Inc. operates with a gross margin of 92.07, reflecting its pricing power and cost economics. The operating margin of -96,427.12 and net profit margin of -1.24M provide insight into operational efficiency.
| Gross Margin | 92.07 |
| Operating Margin | -96,427.12 |
| Pretax Margin | -56,579.33 |
| Profit Margin | -1.24M |
| EBITDA Margin | -96,416.12 |
Stock Splits
Immunotech Laboratories, Inc.'s most recent stock split took place on February 26, 2009 with a 100:1 split ratio.
| Last Split Date | 2/26/2009 |
| Split Ratio | 100:1 |
Scores
Immunotech Laboratories, Inc. posts an Altman Z-Score of -781.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -781.09 |